BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
KLK3
,
T cell receptor signaling pathway
,
Obesity
,
Lung
,
Pharmacogenetics
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
vla 1
Summary
General Info
Curated Studies
Most Correlated Studies
B-cell acute lymphoblastic leukemia REH cells co-cultured with bone marrow mesenchymal stromal cells
Bone-marrow mesenchymal stromal cells from multiple myeloma patients and healthy donors
B-lymphocyte subset responses to LPS induced sepsis
Lungs from mice injection with melanoma B16-F10 exosome protein
Explore Curated Studies Results
Literature
Most Relevant Literature
Sexual dimorphism in reactive oxygen species production and a role for integrin α1β1 in estrogen rec…
VLA-1 Binding to Collagen IV Controls Effector T Cell Suppression by Myeloid-Derived Suppressor Cell…
Outer membrane protein OmpV mediates Salmonella enterica serovar typhimurium adhesion to intestinal …
Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice.
The effects of inhibition and siRNA knockdown of collagen-binding integrins on human umbilical vein …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-00…
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 C…
A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ